Elsevier

Biochemical Pharmacology

Volume 29, Issue 5, 1 March 1980, Pages 707-712
Biochemical Pharmacology

Research paper
Inhibition in vitro of the enzymes of the oxidative pathway of tryptophan metabolism and of nicotinamide nucleotide synthesis by benserazide, carbidopa and isoniazid

https://doi.org/10.1016/0006-2952(80)90544-4Get rights and content

Abstract

The effects of three hydrazine derivatives on the enzymes of the tryptophan oxidative pathway and of nicotinamide nucleotide synthesis have been studied using preparations from rat liver. The compounds used were Benserazide and Carbidopa, two inhibitors of aromatic amino acid decarboxylase used together with dopa in the treatment of Parkinson's disease, and the anti-tubercular agent isoniazid.

All three drugs inhibited tryptophan oxygenase and kynureninase, at concentrations that are likely to be encountered in vivo following administration to patients or experimental animals. Isoniazid, but not Benserazide or Carbidopa, also inhibited 3-hydroxy-anthranilate oxidase and nicotinamide phosphoribosyltransferase. However, these two enzymes were of the drug far in excess of those likely to be encountered in vivo.

On the basis of the in vitro enzyme inhibition studies, it is not possible to explain why patients treated with isoniazid (without supplementary vitamin B6) develop clinical pellagra, while those treated with Benserazide or Carbidopa do not, despite biochemical evidence of niacin deficiency. It is suggested that this difference may be due either to differences in the intake of dietary niacin in these two groups of patients, or more probably to differences in the metabolism of the drugs and in their interactions with enzymes in vivo that are not apparent in vitro.

References (18)

  • D.A. Bender et al.

    Biochem. Pharmac.

    (1977)
  • S.N. Young et al.

    Biochem. Pharmac.

    (1978)
  • M.H. Joseph et al.

    Clin. Chim. Acta

    (1975)
  • F.M. Chiancone
  • Y. Nishizuka et al.
  • S. Pinder et al.
  • R.K. Gholson et al.

    J. biol. Chem.

    (1964)
  • W.J. Johnson et al.

    Int. J. Biochem.

    (1974)
  • B. Petrack et al.

    Biochem. biophys. Res. Commun.

    (1963)
There are more references available in the full text version of this article.

Cited by (31)

  • Kynurenine pathway and human systems

    2020, Experimental Gerontology
    Citation Excerpt :

    This is most likely due to upregulation of TDO, as well as of KAT and down-regulation of KMO, thus increasing the availability of the Kyn substrate (for references, see Badawy and Guillemin, 2019). 3-HAAO is the most active of the KP enzymes (Nishizuka and Hayaishi, 1963; Bender, 1980), which may explain the rapid conversion of 3-HAA to QA. While 3-HAAO inhibition is desirable to limit QA production, it can result in 3-HAA accumulation with potential proinflammatory effects.

  • Hypothesis kynurenic and quinolinic acids: The main players of the kynurenine pathway and opponents in inflammatory disease

    2018, Medical Hypotheses
    Citation Excerpt :

    As shown in Table 1, normal human plasma [3-HAA] is in the low nM range. This could be explained by 3-HAAO being the most active KP enzyme, as demonstrated in rat [53] and mouse [54] liver. The lowest effective [3-HAA] (10 µM) used by Fallarino et al. [52] is 377–1297-fold larger than the normal control plasma values in Table 1, whereas a 100 µM [3-HAA] is a further 10-fold higher.

  • Tryptophan availability for kynurenine pathway metabolism across the life span: Control mechanisms and focus on aging, exercise, diet and nutritional supplements

    2017, Neuropharmacology
    Citation Excerpt :

    However, transamination is enhanced by K or Trp loading or if K hydroxylase or kynureninase activity is inhibited. Because 3-HAA oxidase activity is the highest of all KP enzymes (Nishizuka and Hayaishi, 1963; Bender, 1980), 3-HAA is rapidly converted to quinolinic acid (QA) by non-enzymic cyclization of acroleyl aminofumarate. This latter intermediate is at the cross point of the pathway, which favours QA and hence production of nicotinamide and NAD+.

View all citing articles on Scopus
View full text